The startup develops novel clinical candidate drugs that inhibit the oncogene cMyc and the TOPO 1 enzyme, which are critical drivers of various human cancers. This approach aims to enhance the efficacy of cancer treatment while minimizing toxicity compared to traditional therapies.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many human cancers are driven by oncogenes such as cMyc and the TOPO 1 enzyme. Traditional cancer therapies often lack specificity, leading to significant toxicity and limited efficacy. There is a need for more targeted and effective treatments that can minimize harm to healthy cells while maximizing therapeutic benefits.
Solution
Gibson Oncology is developing novel clinical candidate drugs designed to selectively inhibit the cMyc oncogene and the TOPO 1 enzyme, both of which are critical drivers in various human cancers, including Glioblastoma and Gliomas, for which the company has received Orphan Drug Designation (ODD) from the FDA. This targeted approach aims to enhance the efficacy of cancer treatment by directly addressing the underlying mechanisms of tumor growth and proliferation. By specifically targeting these oncogenes and enzymes, Gibson Oncology's drugs intend to minimize toxicity compared to traditional chemotherapy, which often affects healthy cells along with cancerous ones. The company is finalizing discussions with the NIH to conduct Phase II clinical trials in Glioblastoma (GBM), building upon basic research performed by the NIH, Purdue University, the Robert Preston Tisch Brain Tumor Center at Duke University, and Gibson Oncology itself. Multiple Phase I FDA clinical trials have already been completed by the National Cancer Institute.
Target Audience
The primary target audience includes patients with cancers driven by cMyc and TOPO 1, particularly those with Glioblastoma and Gliomas, as well as medical professionals specializing in oncology and neuro-oncology.
Features
- Selective inhibition of the cMyc oncogene
- Targeted inhibition of the TOPO 1 enzyme
- Orphan Drug Designation (ODD) from the FDA for Glioblastoma and multiple types of Gliomas
- Phase II clinical trials in GBM are in the planning stages with the NIH
- Clinical trials are based on research from the NIH, Purdue University, and Duke University
- Phase I FDA clinical trials completed by the National Cancer Institute